REVVITY, INC. (RVTY)

Revvity is a provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development and from diagnosis to cure. Its specialized focus areas include translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. Its strategy centers on developing innovative products in high-growth markets, investing in research and development, making acquisitions and licensing deals, and advancing the use of artificial intelligence in its offerings and internal operations.

The company reports two segments, Life Sciences and Diagnostics. The excerpt describes Life Sciences in detail. That segment offers products, software and services spanning cell, gene and protein research and the drug discovery and development pipeline. Its offerings include radiometric detection solutions and liquid scintillation and gamma counters. It also sells assay technologies such as HTRF, AlphaLISA and DELFIA, cellular imaging reagents, and recombinant GPCR and ion channel cell lines. Dharmacon gene modulation reagents and the BioLegend portfolio of more than 35,000 SKUs are also part of the segment, covering antibodies, flow cytometry dyes, TotalSeq barcoded antibodies, LEGENDplex and ELISA immunoassays, and MojoSort cell isolation. Instruments include high-content screening and analysis systems (Opera Phenix, Operetta), multimode plate readers, in vivo optical, CT and ultrasound imaging platforms, cell counters and image cytometers, homogenizers, and automated liquid handlers. Software includes the Signals research, notebook, ChemDraw and clinical offerings, Harmony imaging software, and informatics tools such as Katalyst, Luminata, Spectrus, AutoChrom and Percepta. The segment also provides technology and licensing offerings, including the Pin-point base editing platform, the CHOSOURCE CHO expression platform, gene delivery and viral vector services, and preclinical oncology services.

Revvity's Life Sciences customers include global pharmaceutical, biotech and contract research organizations, as well as academic and government institutions. Its products serve applications in research, environmental testing, drug discovery, cell and gene therapy, vaccine and infectious disease research, immunology, neuroscience, oncology and biotherapeutics development. Its informatics software also serves specialty chemical and food science users. The company markets its products and services in more than 160 countries.

Revvity is headquartered in Waltham, Massachusetts, and had approximately 11,000 employees as of December 28, 2025. Its common stock trades on the New York Stock Exchange under the symbol "RVTY", and it is a component of the S&P 500 Index. The excerpt does not describe its suppliers, manufacturing or competitors.